Assessments.
SECONDARY, REMISSION
The primary efficacy endpoint of the study was the change from baseline in HDRS-21 scores at the week 6 visit. The secondary efficacy endpoints were response rate (≥50% reduction from baseline in HDRS-21 score) and remission rate (HDRS-21 < 10) at the week 6 visit. For a full list of assessments please see Figure 1.